HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
54 hedge funds and large institutions have $67M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
1,933% more call options, than puts
Call options by funds: $61K | Put options by funds: $3K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
47% more capital invested
Capital invested by funds: $45.6M → $67M (+$21.4M)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
23% more funds holding
Funds holding: 44 → 54 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$791K |
| 2 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
+$756K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$733K |
| 4 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$733K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$367K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.23M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.23M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$978K |
| 4 |
SIM
Spark Investment Management
New York
|
-$663K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$529K |
HTGM Hedge Fund Activity: Q3 2018 in Review
54 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2018, worth a combined $67M — up 47% from $45.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new HTGM positions and 9 closed out — a net gain of 10 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $791K. The largest seller was Stonepine Capital Management, cutting an estimated $4.23M.
- 54 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2018, up from 44 in Q2 2018.
- Funds reported $67M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2018, up 47% quarter-over-quarter.
- 19 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2018 and 9 closed out, a net change of +10 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2018 was Russell Investments Group, an estimated $791K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2018 was Stonepine Capital Management, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2018.